Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan for Right Ventricular Strain in Scleroderma Pre-PAH
NCT02169752Terminated
- Sponsor
- National Jewish Health
- Start
- Sep 2012
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Ambrisentan with Placebo (2 arms). Primary endpoint: Improvement in right ventricular (RV) myocardio strain at 6 months. Started Sep 2012; status: terminated.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02169752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169752.